RxDoctor Payments Data

Tie Wei, MD

Family Medicine · Bellevue, WANPI 1336264761

Payments from drug & device makers

$2,398in general payments, 2019–2025

Across 18 payments — averaging $133.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$640
  • Novo Nordisk$451
  • Johnson & Johnson$281
  • AstraZeneca$257
  • Phathom Pharmaceuticals, Inc.$244
  • Amgen$147
  • plus $377 from 4 others

What the payments were for

  • Consulting fees$64027%
  • Food & beverage$1,75873%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,398 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$46,392
Medicare patients
140
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$61,178
EliquisApixaban23$32,474
OzempicSemaglutide13$15,242
Atorvastatin Calcium380$2,990
Losartan Potassium105$1,155
Naltrexone Hcl17$1,019
Amlodipine Besylate154$881
Tamsulosin Hcl67$821
Lisinopril110$810
Rosuvastatin Calcium64$803
Levothyroxine Sodium89$665
Metformin Hcl ErMetformin Hcl100$637
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide38$517
Allopurinol61$496
Finasteride43$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$115$61,17839 claims
Novo NordiskOzempic$451$15,24213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →